Drug Database
PI

pitavastatin + valsartan (Livalsartan / Livasartan)

✓ Approved

JW Pharmaceutical · AGTR1 · Small Molecule

What is pitavastatin + valsartan?

pitavastatin + valsartan is a small molecule developed by JW Pharmaceutical. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesLivalsartan, Livasartan
CompanyJW Pharmaceutical
Drug ClassSmall Molecule
Molecular TargetAGTR1, HMGCR
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, JW Pharmaceutical

Mechanism of Action

Molecular Targets

pitavastatin + valsartan acts on 2 molecular targets:

AGTR1angiotensin II receptor type 1 (HAT1R, AT1)
HMGCR3-hydroxy-3-methylglutaryl-CoA reductase (LDLCQ3, LGMDR28)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

pitavastatin + valsartan is developed for 2 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Metabolism and nutrition disordersHypercholesterolaemia✓ Approved
Vascular disordersHypertension✓ Approved

Related Research Articles

PubMedRSC advances2026-11-11

Harnessing of terpenoids to unlock new solid forms of valsartan.

Baier Daniel M DM, Hendrickx Leeroy L, Gieling Job J, Carvalho Ana C S ACS et al.

Valsartan forms three previously unreported crystalline inclusion compounds with the terpenoids menthone, carvone, and eucalyptol. Solid-state nuclear magnetic resonance (NMR), X-ray diffraction, and thermal analysis confirm the formation of distinct crystalline materials in which sub-stoichiometric amounts of terpenoids are incorporated into a valsartan host framework through reversible non-covalent interactions. These findings identify naturally derived terpenoids as an effective and underexplored class of solid-form modulators for pharmaceutical development.

PMID 43011546
Read full article →
PubMedThe Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology2026-11-11

The efficacy of add on cardiac resynchronization therapy (CRT) to symptomatic patients with heart failure with reduced ejection fraction on sacubitril/valsartan treatment as regards left ventricle reverse remodeling and functional improvement.

Nazmy Nour El Din Mohamed NEDM, Eldamanhory Hayam Mohamed HM, Badran Haitham Abdelfatah HA, Hassan Hassan Shehata HS

Heart failure (HF) represents a substantial worldwide healthcare burden, with nearly 26 million people affected. CRT is widely recommended for HFrEF patients with QRS duration > 150 msec, but its role in those with QRS duration of 130-149 msec remains debated. The objective was to evaluate whether adding CRT improves LV reverse remodeling and functional status in symptomatic HFrEF patients receiving maximally tolerated sacubitril/valsartan with QRS duration of 130-149 msec. This study included 100 patients with HFrEF (≤ 35%) treated with maximally tolerated sacubitril/valsartan and having LBBB morphology with QRS duration of 130-149 msec. Patients were classified into two groups: those receiving CRT and those maintained on medical therapy without CRT. Clinical status, QRS duration, and echocardiographic findings were reassessed after 6 months and compared between groups. At 6 months, NYHA class improvement occurred more frequently with CRT than without CRT (37 vs. 20 patients, P = 0.004). The decline in end-systolic volume was greater in the CRT group (mean change, 11.42 ± 7.30 vs. 3.54 ± 6.41, P < 0.001). Ejection fraction also showed greater improvement with CRT (mean change, 4.24 ± 3.17 vs. 1.30 ± 2.35, P < 0.001). Hospitalization occurred less frequently in the CRT group (46% vs. 70%, P = 0.03). No deaths were observed in either group throughout follow-up. In symptomatic HFrEF patients receiving maximally tolerated sacubitril/valsartan with QRS duration of 130-149 msec, adjunctive CRT was associated with greater LV reverse remodeling, improved functional status, and fewer hospitalizations.

PMID 43009735
Read full article →
PubMedZhonghua nan ke xue = National journal of andrology2026-11-11

[Adverse drug reaction signals of statin-induced male sexual dysfunction: Mining and analysis based on the FDA Adverse Event Reporting System].

Gao Wen W, Sun Ling L, An Xiaotong X, DU Wei W et al.

Objective To mine and analyze the adverse drug reaction (ADR) signals of statin-induced male sexual dysfunction based on the database of the FDA Adverse Event Reporting System (FAERS). Methods We searched the FAERS database for the case reports published from the first quarter of 2004 to the fourth quarter of 2023, in which statins were shown as the primary suspected drugs for sexual dysfunction ADRs in male patients, and subjected the reports to standardized processing according to the WHO Adverse Reaction Terminology. We detected the ADR signals using the reporting odds ratio (ROR), proportional reporting ratio (PRR), and Bayesian confidence propagation neural network (BCPNN). Results A total of 2 408 adverse event reports of male sexual dysfunction associated with statins as the primary suspected drug were extracted from the FAERS database, involving 2 173 patients (some patients reported multiple adverse events).The largest proportion of the patients (47.22% ［1 026/2 173］) were aged 18－65 years old, primarily from the United States (n = 897, 41.28%), the largest number of cases reported in 2010 (n = 183, 8.42%), and atorvastatin ranking the first for intervention (n= 990, 41.11%), followed by rosuvastatin (n = 639, 26.54%) and simvastatin (n = 502, 20.85%). Totally, 28 high-risk ADR signals for male sexual dysfunction were identified, among which, hypoesthesia was found related to 7 statins (atorvastatin, rosuvastatin, simvastatin, pravastatin, fluvastatin, lovastatin, and pitavastatin), and ED associated with 6 (atorvastatin, rosuvastatin, simvastatin, pravastatin, ezetimibe and lovastatin).ConclusionSufficient medication evaluation is necessitated prior to clinical application of statins, especially for patients aged 18－65 years, with caution against the development of male sexual dysfunction within 30 days of administration. Clinicians should pay attention to ADR signals beyond those listed in the drug package inserts to ensure the safety of medication.

PMID 43012181
Read full article →
PubMedInternational journal of heart failure2026-11-11

Natriuretic Peptides for Predicting Treatment Response in Heart Failure: Insights From Recent Randomized Controlled Trials.

Oh Ha Eun HE, Hyun Junho J

N-terminal pro-B-type natriuretic peptide (NT-proBNP) has emerged as a cornerstone biomarker in heart failure (HF), serving as a diagnostic, prognostic, and pharmacodynamic tool in randomized controlled trials. Recent HF trials have generated substantial evidence regarding 2 interrelated roles: (1) the relationship between baseline NT-proBNP levels and differential treatment efficacy across drug classes, and (2) the proportional relationship between NT-proBNP reduction and clinical outcome improvement. We synthesize data from pivotal trials of sacubitril/valsartan (angiotensin receptor-neprilysin inhibitor, ARNI), sodium-glucose cotransporter 2 (SGLT2) inhibitors, mineralocorticoid receptor antagonists (MRAs), vericiguat, and omecamtiv mecarbil. Across trials in both HF with reduced ejection fraction and HF with mildly reduced or preserved ejection fraction, some drug classes including ARNI, SGLT2 inhibitors, MRA, and device therapies demonstrated consistent relative treatment benefits regardless of baseline NT-proBNP levels. Notable exceptions were vericiguat, a soluble guanylate cyclase stimulator, where patients with higher baseline NT-proBNP derived no benefit; omecamtiv mecarbil, which showed selective benefit in patients with higher NT-proBNP levels; and spironolactone in HFpEF, where benefit was concentrated in patients with the lowest baseline NT-proBNP. With respect to NT-proBNP dynamics, a geometric mean ratio of on-treatment to baseline NT-proBNP consistently parallels the hazard ratio for clinical outcomes across ARNI trials, supporting NT-proBNP change as a robust surrogate endpoint. SGLT2 inhibitors consistently show clinical benefit exceeding the extent of NT-proBNP reduction, reflecting pleiotropic mechanisms. These insights position NT-proBNP not merely as a prognostic marker, but as an outcome-predictive biomarker that may inform patient selection and response monitoring in precision HF management.

PMID 43011112
Read full article →
PubMedEuropean heart journal2026-11-10

Sacubitril/valsartan for radiation-induced heart disease in children: preclinical and clinical findings.

Zhao Li L, Guo Xia X, Tang Yuanling Y, Hua Yimin Y et al.

Radiation-induced heart disease (RIHD) is a life-threatening sequela for cancer survivors. A proactive preventive strategy is urgently needed but remains elusive, particularly for the vulnerable paediatric population where prospective data are scarce. To address this gap, this study aimed to evaluate the prophylactic efficacy of sacubitril/valsartan against RIHD in children through a comprehensive translational research pipeline. A prospective observational study was first conducted in 40 paediatric solid tumour patients, comparing cardiac function before and 1 week after radiotherapy, with 80 healthy controls. A juvenile rat RIHD model was then established, in which the efficacy of sacubitril/valsartan was assessed and validated through longitudinal echocardiography, cardiac magnetic resonance imaging, histopathology, bulk RNA-seq, and single-nucleus RNA-seq. Finally, a prospective clinical cohort (n = 15 sacubitril/valsartan, n = 15 control) was conducted in paediatric patients post-radiotherapy, with a 12-month follow-up for efficacy and safety. In paediatric patients, radiotherapy significantly impaired biventricular function, notably reducing left ventricular global longitudinal strain, and mean heart radiation dose was significantly correlated with cardiac function impairment. In juvenile rats, sacubitril/valsartan attenuated pathological ventricular wall thickening, myocardial fibrosis, diastolic dysfunction, and perfusion deficits. Mechanistically, it mitigated endothelial cell damage and immune cell activation, promoted a macrophage phenotypic shift from M1 to M2, suppressed fibroblast-to-myofibroblast transition, and broadly attenuated pro-fibrotic and inflammatory cell-cell communication. In the clinical cohort, sacubitril/valsartan significantly improved left ventricular global longitudinal strain and aortic compliance vs controls, with a favourable safety profile. This first-in-kind translational study demonstrates that early prophylaxis with sacubitril/valsartan is a feasible and effective strategy to mitigate radiation-induced cardiotoxicity in children. These findings, underpinned by multi-modal validation from bench to bedside, challenge the reactive management paradigm in paediatric cardio-oncology and establish a foundational evidence base for a new standard of proactive heart care in childhood cancer survivors.

PMID 43004603
Read full article →
PubMedCardiovascular diagnosis and therapy2026-11-06

Echocardiographic response and predictors of reverse remodeling after sacubitril/valsartan in de novo heart failure with reduced ejection fraction: cohort study.

Moon In Tae IT, Park Sung Hun SH, Chin Jung Yeon JY

Sacubitril/valsartan (angiotensin receptor-neprilysin inhibitor, ARNI) improves outcomes in heart failure with reduced ejection fraction (HFrEF), yet treatment response varies and predictors of response remain incompletely defined. We aimed to evaluate real-world echocardiographic responses to ARNI and identify predictors of favorable response in patients with newly diagnosed HFrEF. Consecutive patients who initiated ARNI at Uijeongbu Eulji University Hospital between March 2021 and August 2024 were prospectively enrolled. Echocardiographic reverse remodeling was assessed by changes in left ventricular (LV) ejection fraction (EF). Based on the degree of echocardiographic response, patients were categorized as nonresponders [follow-up left ventricular ejection fraction (LVEF) <40% and an absolute increased in LVEF <10%], partial responders (follow-up LVEF ≥40% and <50%, or an absolute increase in LVEF ≥10% with follow-up LVEF <50%), or super responders (follow-up LVEF ≥50%). Clinical outcomes were assessed using Kaplan-Meier analysis, and predictors of response were evaluated using multivariable logistic regression. Among 392 patients who completed follow-up echocardiography (median follow-up interval, 11.0 months), 116 (29.6%) were nonresponders, 110 (28.0%) were partial responders, and 166 (42.3%) were super responders with a recovery of LVEF ≥50%. During a median follow-up of 708 days, nonresponders experienced significantly higher rates of clinical events, including death or heart failure rehospitalization, compared with responders (P<0.001). In multivariable analysis, higher baseline systolic blood pressure [SBP; odds ratio (OR), 1.249; 95% confidence interval (CI): 1.120-1.400] and smaller LV end-diastolic volume (OR 0.919; 95% CI: 0.869-0.970) were independently associated with favorable echocardiographic response. Although a substantial proportion of patients did not achieve ARNI doses ≥200 mg/day, exploratory analysis did not demonstrate a significant association between ARNI dose and echocardiographic response or clinical outcomes. In this real-world cohort study, ARNI therapy was associated with substantial reverse remodeling and improved clinical outcomes despite low rates of target-dose attainment. Baseline SBP and LV remodeling parameters were associated with treatment response, supporting individualized ARNI titration strategies in clinical practice.

PMID 42990985
Read full article →

+7463 more articles available with a free account

Sign up free to view all articles →

Ask about pitavastatin + valsartan